Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Receivables - Other (2017 - 2023)

Historic Receivables - Other for BeOne Medicines (BEIGF) over the last 7 years, with Q4 2023 value amounting to $1.7 million.

  • BeOne Medicines' Receivables - Other fell 4290.89% to $1.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.7 million, marking a year-over-year decrease of 4290.89%. This contributed to the annual value of $1.7 million for FY2023, which is 4290.89% down from last year.
  • BeOne Medicines' Receivables - Other amounted to $1.7 million in Q4 2023, which was down 4290.89% from $1.6 million recorded in Q3 2023.
  • In the past 5 years, BeOne Medicines' Receivables - Other ranged from a high of $12.7 million in Q4 2020 and a low of $1.3 million during Q1 2023
  • Its 5-year average for Receivables - Other is $4.3 million, with a median of $3.5 million in 2019.
  • As far as peak fluctuations go, BeOne Medicines' Receivables - Other plummeted by 7756.62% in 2019, and later soared by 55481.37% in 2020.
  • Quarter analysis of 5 years shows BeOne Medicines' Receivables - Other stood at $1.9 million in 2019, then surged by 554.81% to $12.7 million in 2020, then plummeted by 60.07% to $5.1 million in 2021, then plummeted by 39.85% to $3.0 million in 2022, then crashed by 42.91% to $1.7 million in 2023.
  • Its Receivables - Other was $1.7 million in Q4 2023, compared to $1.6 million in Q3 2023 and $2.0 million in Q2 2023.